POPULARITY
Categories
156 episodes with bcps
65 episodes with bcps
56 episodes with bcps
89 episodes with bcps
32 episodes with bcps
73 episodes with bcps
41 episodes with bcps
29 episodes with bcps
28 episodes with bcps
48 episodes with bcps
19 episodes with bcps
20 episodes with bcps
19 episodes with bcps
18 episodes with bcps
13 episodes with bcps
22 episodes with bcps
11 episodes with bcps
11 episodes with bcps
14 episodes with bcps
10 episodes with bcps
11 episodes with bcps
9 episodes with bcps
18 episodes with bcps
6 episodes with bcps
8 episodes with bcps
14 episodes with bcps
8 episodes with bcps
9 episodes with bcps
7 episodes with bcps
4 episodes with bcps
14 episodes with bcps
14 episodes with bcps
8 episodes with bcps
10 episodes with bcps
9 episodes with bcps
4 episodes with bcps
8 episodes with bcps
4 episodes with bcps
6 episodes with bcps
4 episodes with bcps
5 episodes with bcps
4 episodes with bcps
4 episodes with bcps
4 episodes with bcps
6 episodes with bcps
5 episodes with bcps
10 episodes with bcps
63 episodes with bcps
4 episodes with bcps
2 episodes with bcps
3 episodes with bcps
3 episodes with bcps
8 episodes with bcps
3 episodes with bcps
Sustaining critical care delivery in today's healthcare environment requires more than resilience—it also calls for collective solutions to systemic challenges. In this episode of the Society of Critical Care Medicine (SCCM) Podcast, Past President Jose L. Pascual, MD, PhD, FRCS(C), FACS, FCCM, elaborates on the session presented during the 2026 Critical Care Congress, Critical Care Under Pressure: Sustaining the Workforce and Infrastructure Amid Rising Demands. Joined by host Marilyn Bulloch, PharmD, BCPS, FCCM, Dr. Pascual examines the complex forces reshaping critical care, from shrinking ICU capacity and hospital closures to persistent workforce shortages and shifting training pipelines. He highlights concerning trends such as reduced entry into certain critical care pathways, particularly anesthesiology. At the same time, he points to encouraging growth in other pathways, with increasing participation from clinicians in emergency medicine, neurology, and surgery. The conversation underscores disparities in access to care, particularly for rural and community hospitals. Dr. Pascual explores the tension between the regionalization of specialized care and the need to maintain equitable access across health systems, emphasizing the importance of thoughtful resource distribution and collaboration across institutions. Beyond workforce numbers, the evolution of leadership in critical care is also impactful, including the migration of experienced clinicians into administrative roles and the potential need for cyclical leadership models that maintain clinical engagement. Meeting these challenges requires innovation and cooperation. Dr. Pascual highlights advancements in education, particularly the expansion of simulation-based training, as critical tools for maintaining competency and improving team performance. Resources referenced in this episode: 2026 Congress Digital
In this episode of Mind the Meds, Erica Marini, PharmD, highlights information from the European Stroke Organization Conference include encouraging data on asundexian(Bayer), a factor XIa inhibitor showing reduced recurrent ischemic stroke risk without increased bleeding, as well as positive results from three trials of tirofiban in acute ischemic stroke settings. On the multiple sclerosis (MS) front, Marini covers the FDA approval of ocrelizumab (Ocrevus; Genentech) for pediatric relapsing-remitting MS in children 10 and older, a new study supporting early use of high-efficacy agents in pediatric MS, and 2 Lancet publications on ocrelizumab — one examining higher weight-adjusted dosing (which did not improve disability progression) and one confirming benefit in a broader primary progressive MS population. She also briefly discusses PADOVA (NCT04777331), a phase 2b trial of prasinezumab in early Parkinson's disease, which failed to meet its primary end point.The bulk of the episode is a discussion with guest Millad Sobhanian, PharmD, BCPS, clinical pharmacy specialist in neurology at the University of Maryland, focused on Alzheimer disease. They cover dextromethorphan/bupropion (Auvelity; Axsome Therapeutics), newly approved in April 2026 for agitation associated with Alzheimer dementia. Sobhanian walks through key safety considerations—including additive NMDA antagonism if combined with memantine, cardiovascular risks from the bupropion component, and the ever-present black box warning on antipsychotics in dementia patients—while both note that the efficacy data, though statistically significant, shows modest clinical effect sizes compared to the threshold for meaningful within-patient change.The conversation then turns to lecanemab's subcutaneous initiation formulation (Leqembi Iqlik; Eisai, Biogen), whose FDA decision has been delayed to about August 2026 as regulators seek more data on bioavailability and ARIA monitoring in the at-home setting. Sobhanian shares his real-world perspective on anti-amyloid therapy, describing a patient population that is typically early-stage, high-functioning, and has a mean age of about 60 to 70 years, and emphasizing the pharmacist's role in expectation-setting around the modest but potentially cumulative slowing of cognitive decline. The episode closes with a thorough discussion of the April 2026 Cochrane review on amyloid-targeting monoclonal antibodies, which both Marini and Sobhanian find overly broad in its conclusions. They note limitations such as the inclusion of withdrawn agents like aducanumab (Aduhelm; Biogen), heterogeneous inclusion criteria across trials, and an 18-month study horizon that may be too short to capture the full benefit suggested by longer-term open-label extension data.Key Takeaways:1. New options for Alzheimer's agitation exist, but fit carefully into the treatment algorithm. Dextromethorphan/bupropion offers a novel NMDA-based mechanism for treating agitation in Alzheimer dementia, but its clinical effect size is modest, and it carries meaningful safety considerations—particularly around the bupropion component in elderly patients. Like all pharmacologic options in this space, it remains a later-line choice after nonpharmacologic interventions have been exhausted, and medication reconciliation is critical given its interaction potential with memantine and CYP2D6 inhibitors.2. Anti-amyloid therapies are imperfect but not ready to be written off. The April 2026 Cochrane review drew significant attention with its conclusion that anti-amyloid monoclonal antibodies produce only trivial cognitive benefits, but its findings are limited by the inclusion of older, withdrawn agents, heterogeneous trial populations, and an 18-month time horizon that may be too short to capture the full trajectory of benefit.3. The pharmacist's role in anti-amyloid therapy goes well beyond dispensing. As illustrated by Sobhanian's practice at the University of Maryland, clinical pharmacists embedded in neurology clinics play a critical role in patient selection, expectation-setting, ARIA counseling, and informed decision-making for patients considering anti-amyloid therapy—a complex, high-stakes treatment decision that these patients and their caregivers should never be navigating alone.
Early detection of chronic kidney disease (CKD) means little if it does not lead to timely treatment, yet a significant gap persists between when CKD is found and when evidence-based therapies are started. That disconnect is the focus of the second episode of Beyond the Silo: Integrated Care Across the CRM Continuum, a podcast series from The American Journal of Managed Care®, in which Ralph Riello, PharmD, BCPS, leads a conversation with Nihar Desai, MD, MPH, on how to shift CKD care from a reactive, late-stage model to one that is proactive, pathway-driven, and equitable. The discussion builds on the first episode's focus on urine albumin-to-creatinine ratio underutilization, stipulating that screening has occurred and asking what must happen next. You can listen to the first episode here: https://www.ajmc.com/link/89943
Listen in as our expert panel unpacks updated definitions of complicated vs. uncomplicated urinary tract infections, navigates antibiotic selection and duration, and shares the latest evidence-based strategies to stop recurrent UTIs in their tracks.Special guests:Dana Bowers, PharmD, BCPS, BCIDPAssociate ProfessorWashington State UniversityAkshith Dass, PharmD, MPH, BCPS, BCIDPAssistant Professor of Pharmacy PracticeNortheast Ohio Medical UniversityPharmacy Clinical Specialist Cleveland Clinic Mercy HospitalYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Craig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in April 2026.
Season 10, Episode 14: Optimizing Access Through OOLD In this episode of the PQI Podcast, we explore Oncology Optimized Limited Distribution (OOLD) and its growing importance within patient-centered oncology care. Guests Jonas Congelli, RPh, and Ken Komorny, PharmD, BCPS, discuss how distribution models impact oncology practices, care coordination, and the patient experience, while highlighting the critical role of medically integrated pharmacy services in supporting timely therapy initiation, education, adherence, and adverse event management. Jonas shares the vision behind OOLD and how medically integrated oncology teams help streamline care for patients receiving oral anticancer therapies. Ken provides insight into Moffitt Cancer Center's experience navigating operational, financial, and policy challenges related to specialty pharmacy access, including advocacy efforts. The conversation also highlights how oncology practices, manufacturers, and advocacy organizations can work together to preserve coordinated care models that prioritize patient safety, communication, and continuity of care. Throughout the episode, the discussion reinforces the value of multidisciplinary collaboration and innovation in shaping the future of oncology pharmacy practice and improving outcomes for patients nationwide. Learn more about NCODA and NCODA's OOLD initiatives here.View the poster Ken discussed here.
Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Anastasiya Shor, director of the drug information center and assistant professor at Touro College of Pharmacy. She shares what inspired her to pursue a career in pharmacy and offers insight into the vital role pharmacists play in supporting patients. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Melatonin—widely available over the counter and often perceived as“natural and safe”—has become increasingly used by caregivers toaddress sleep disturbances in children and adolescents, yet its properrole and safety profile in pediatrics remain nuanced and evolving. Thiscourse examines current evidence on indications such as insomnia andcircadian rhythm sleep disorders, highlights concerns aboutunregulated supplement use and adverse effects, and reviews practicalconsiderations for safe and informed use in pediatric patients. You willgain insight into how to support caregivers with balanced counseling,emphasize behavioral and environmental strategies, and apply clinicaljudgment when melatonin is being considered for sleep managementin pediatric patients.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTMonica Bogenschutz, PharmD, BCPS, BCPPS, DPLA, FPPAPediatric Clinical Pharmacist and PGY2 Pediatric Pharmacy Residency Program Director at UW Health Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe common pediatric indications and available evidence for melatonin use in children and adolescents2. Identify pharmacist considerations related to safety, dosing, behavioral counseling, and monitoring when melatonin is recommended or used in pediatric patients.Rachel Maynard and Monica Bogenschutz have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-222-H01-P Initial release date: 5/25/2026Expiration date: 5/25/2027Additional CPE details can be found here.
Melatonin—widely available over the counter and often perceived as “natural and safe”—has become increasingly used by caregivers to address sleep disturbances in children and adolescents, yet its proper role and safety profile in pediatrics remain nuanced and evolving. This course examines current evidence on indications such as insomnia and circadian rhythm sleep disorders, highlights concerns about unregulated supplement use and adverse effects, and reviews practical considerations for safe and informed use in pediatric patients. You will gain insight into how to support caregivers with balanced counseling, emphasize behavioral and environmental strategies, and apply clinical judgment when melatonin is being considered for sleep management in pediatric patients.HOSTRachel Maynard, PharmD GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTMonica Bogenschutz, PharmD, BCPS, BCPPS, DPLA, FPPAPediatric Clinical Pharmacist and PGY2 Pediatric Pharmacy Residency Program Director at UW HealthGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: - Compliance and licensure CE - GameChangers Clinical Updates- Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe common pediatric indications and available evidence for melatonin use in children and adolescents2. Identify pharmacist considerations related to safety, dosing, behavioral counseling, and monitoring when melatonin is recommended or used in pediatric patients.Rachel Maynard and Monica Bogenschutz have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-222-H01-P Initial release date: 5/25/2026Expiration date: 5/25/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …
Older adults consist of approximately half of the patients in the ICU, with that number expected to grow in the coming decades. In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn N. Bulloch, PharmD, BCPS, FCCM, is joined by Bram Rochwerg, MD, MSc(Epi), FRCPC, FCCM, and Lauren E. Ferrante, MD, MHS, to discusses new guidelines on caring for older adults in the ICU and the difficulties in finding research that focuses on those patients. The guidelines, “Society of Critical Care Medicine Guidelines on Caring for Older Adults in the ICU,” will be published in an upcoming issue of Critical Care Medicine. The panel details the process and methodology behind the guidelines, the dearth of studies focusing on older patients in the ICU, and the difficulty of finding studies that enroll older adults who are on multiple medications. The guidelines offer two conditional recommendations and offer priorities for aging-friendly research topics to help provide stronger guidance in the future. Bram Rochwerg, MD, MSc(Epi), FRCPC, FCCM, is an associate professor, intensivist, and researcher based at McMaster University in Hamilton, Ontario, Canada, who focuses on intravenous fluid use in sepsis, the role of corticosteroids in acute hypoxemic respiratory failure, and clinical practice guideline methodology. Lauren E. Ferrante, MD, MHS, is an associate professor of medicine in the section of pulmonary, critical care, and sleep medicine at the Yale School of Medicine; director of the operations core of the Yale Claude D. Pepper Older Americans Independence Center; and an attending physician in the medical intensive care unit at Yale-New Haven Hospital in New Haven, Connecticut, USA. Resources referenced in this podcast: Society of Critical Care Medicine Guidelines on Caring for Older Adults in the ICU Compassionate and Evidence-Based Care (session from the 2026 Critical Care Congress) Congress Digital Geriatric Knowledge Education Group Thought Leader: Why the 4Ms Approach to Critical Care Improves Quality (session from the 2025 Critical Care Congress)
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bethany Lussier, MD Patients often present with respiratory symptoms that don't quite align with typical pulmonary findings. So what clues should raise our suspicion that something beyond primary lung disease might be driving their condition? Joining Dr. Charles Turck to talk about the pulmonologist's role in identifying respiratory manifestations of thymidine kinase 2 deficiency (TK2d) is Dr. Bethany Lussier. She shares the hallmark features to look out for, like orthopnea and hypoventilation, as well as best practices for using pulmonary function testing and inspiratory pressure measures to distinguish muscle weakness from primary lung disease. Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center in Dallas, where she's also a member of the Division of Pulmonary and Critical Care Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate with pathologic complete response. Dr. Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as the Clinical Research Division at the Fred Hutchinson Cancer Center, where he's also the Medical Director of the International Program and of local and regional outreach.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That's why Dr. Charles Turck speaks with Dr. Maggie Emerson about how we can best partner with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.
CommonSpirit Health hosted a Grand Rounds session discussing pediatric antimicrobial stewardship guidelines for upper respiratory infections.Speakers:Michael Dudas, MD, Chief, VMMC Pediatrics, Deputy Chief, VMMC Primary Care, Chair, CommonSpirit Pediatric CollaborativeLilia Parra-Roide, MD, Chair, Pediatrics, Professor of Pediatrics, Creighton University School of MedicineScott Piazza, DO, Medical Director of Informatics for Pacific Central Coast Health Centers, Adjunct Faculty for the Marian Family Medicine Residency Program, Chair, Department of Family and Community Medicine, Marian Regional Medical CenterClaire Swartwood, PharmD, BCPS, BCIDP, Clinical Pharmacist — Antimicrobial Stewardship Program, Department of Pharmacy, Mountain RegionKenneth Foerster, MD, MBA, Senior Regional Medical Director, Prompt Care, Urgent Care, COHE, Virginia Mason Franciscan HealthModerator:Ankita Sagar, MD, MPH, FACP, FAMWA, System Vice President, Clinical Transformation and Well-Being, CommonSpirit Health
In this episode, Paul Green, Pharm.D., MHA, BCPS, CPEL, DPLA - Director of Pharmacy Services, Westchester Medical Center, discusses how pharmacy is evolving from a cost center to a key driver of clinical, operational, and financial value. He shares insights on technology integration, workforce sustainability, and building a proactive pharmacy strategy aligned with broader health system goals.
Listen in as our expert panel covers the latest evidence on using menopausal hormone therapy and nonhormonal options for treatment of vasomotor symptoms (hot flashes, etc). You'll also hear experts discuss treatments for genitourinary symptoms (vaginal dryness, etc) as well as low libido and brain fog.Special guests:Veronica Vernon, PharmD, BCPS, BCACP, MSCP, FAPhA Associate Professor, Chair of Pharmacy PracticeButler UniversitySarah M. Westberg, PharmD, FCCP, BCPSAssociate Dean for Professional Affairs Professor, College of PharmacyUniversity of MinnesotaYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby-Stewart, MDAssociate Director, Honor Health Family Medicine Residency ProgramClinical Professor of Family, Community & Occupational MedicineThe University of Arizona College of Medicine – PhoenixCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2026.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Guru P. Sonpavde, MD What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their discussion highlights how ctDNA monitoring identifies early recurrence risk, captures real-time immunotherapy activity, and positions ctDNA clearance as a powerful prognostic marker. Dr. Sonpavde is the Medical Director of Genitourinary Oncology and the Phase I Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando.
"They are small, powerful little nuggets. They are actually small signaling proteins that our immune cells use to communicate. They really help regulate immune activation or inflammation and even the growth and survival of immune cells. When cytokines are used therapeutically in oncology, they help to stimulate immune cells such as T cells or natural killer cells to better recognize and attack cancer cells," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center of Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the cytokine drug class. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours (including 30 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 24, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of cytokines to provide appropriate education and to safely administer related therapies. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis ONS Voice articles: FDA Approves Nogapendekin Alfa Inbakicept-Pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Oncology Drug Reference Sheet: Motixafortide ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) and 2024 Drug Supplement Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Clinical Journal of Oncology Nursing article: Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Nursing Considerations What's Old Is New Again, Unfortunately ONS Symptom Interventions Colony-Stimulating Factors Including Biosimilars for At-Risk Patients for Prevention of Infection: General Platelet Growth Factors for Prevention of Bleeding National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Cytokines are actually among some of the earliest forms of immunotherapy used in the treatment of cancer, and it really goes back to the 1980s and the 1990s. We're talking therapies like interferon [alpha] or interleukin-2 that were used to stimulate the immune system, with the idea that they would recognize and attack cancer cells, particularly in diseases like metastatic melanoma and renal cell carcinoma. What made these therapies unique was that although the overall response rates were relatively modest, when patients did respond, those responses could be very durable and sometimes long lasting. And that observation was really important for the field of oncology, because it was part of the process that demonstrated that the immune system could potentially control cancer in really meaningful ways." TS 1:49 "One nice new example of an engineered cytokine is nogapendekin alfa inbakicept, which is quite the tongue twister to say. … This agent is really interesting because it's an engineered interleukin-15 receptor agonist that works on stimulating natural killer cells and CD8-positive T cells. And what makes this so interesting is that it's used in combination with a medication that probably some of us are familiar with—good old BCG—for patients specifically with invasive bladder cancer. The other really interesting thing about this new therapy is the fact that it is one of our first ones to be engineered in a combination fashion. So the nogapendekin alfa is combined with a receptor component that is called inbakicept. And what happens is it forms a complex to enhance signaling and prolong the activity of the cytokine." TS 7:50 "When you're looking at our therapeutic cytokines, those tend to produce larger-scale systemic inflammatory effects leading to much more global side effect reactions, while your supportive care cytokines are more commonly associated with either bone marrow stimulation effects or hematologic changes." TS 14:01 "Regardless of what type of cytokine therapy may you be using, across the board, early recognition of the symptoms and proactive supportive care are really important. And this is where many of our oncology nurses play such a critical role in identifying changes that are happening in real time to the patient's condition and helping to coordinate, relay information to the rest of the providing team so that timely interventions can occur for the best care of the patient." TS 18:01 "The other fascinating thing about these cytokines is that they're not being used as monotherapy anymore. They're now being looked at in combination with other therapies or even other immunotherapies like our checkpoint inhibitors. They're being looked at in the sense that they may be able to help expand and further activate immune cells that our current therapies rely on. And so it's really interesting that while cytokines were some of the earliest forms of cancer immunotherapy, they're now being reimagined as part of modern combination strategies designed to really further help enhance the immune responses against cancer." TS 29:08
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/PMA865. CME/CPE/IPCE credit will be available until April 8, 2027.Partners in Shingles Prevention: Turning Patient Insights Into Collaborative Immunization Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/PMA865. CME/CPE/IPCE credit will be available until April 8, 2027.Partners in Shingles Prevention: Turning Patient Insights Into Collaborative Immunization Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/PMA865. CME/CPE/IPCE credit will be available until April 8, 2027.Partners in Shingles Prevention: Turning Patient Insights Into Collaborative Immunization Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/PMA865. CME/CPE/IPCE credit will be available until April 8, 2027.Partners in Shingles Prevention: Turning Patient Insights Into Collaborative Immunization Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/PMA865. CME/CPE/IPCE credit will be available until April 8, 2027.Partners in Shingles Prevention: Turning Patient Insights Into Collaborative Immunization Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/PMA865. CME/CPE/IPCE credit will be available until April 8, 2027.Partners in Shingles Prevention: Turning Patient Insights Into Collaborative Immunization Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
AI is rapidly reshaping pharmacy practice, raising both concern and opportunity for healthcare teams. Vizient host Kerry Schwarz is joined by Dr. Jason Chou, Vice President of the System Pharmacy Service Line, and Dr. Catherine Oliver, System AVP of Clinical Pharmacy Services at Ochsner Health, to explore how AI is improving efficiency while redefining how pharmacy teams spend their time. They discuss where technology is already making an impact and where its limits still require human expertise. Guest Speakers: Dr. Jason Chou, Pharm.D., MS Vice President, System Pharmacy Service Line Ochsner Health Dr. Catherine Oliver, Pharm.D., BCPS, DPLA, CPGx System AVP, Clinical Pharmacy Services Ochsner Health Host Dr. Kerry Schwarz, Pharm.D., MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence Shownotes: 00:05 — Introduction Announcer welcomes listeners to VerifiedRx, produced by the Vizient Center for Pharmacy Practice Excellence. 00:14 — Episode Overview Host Kerry introduces the topic: the role of artificial intelligence (AI) in healthcare and pharmacy. Key themes: Addressing fears of job replacement Identifying real-world use cases Understanding limitations of AI Practical strategies for adoption Guests: Dr. Jason Chou, VP, System Pharmacy Service Line, Ochsner Health Dr. Catherine Oliver, System AVP, Clinical Pharmacy Services, Ochsner Health 01:04 — Will AI Replace Healthcare Jobs? Concern exists, but largely driven by misunderstanding AI is expected to: Augment, not replace, pharmacy roles Improve efficiency in daily workflows AI is not capable of: Independent clinical judgment Meaningful patient interactions Human elements—trust, empathy, and nuance—remain essential. 02:20 — Where AI Can Add Value Today Focus should shift from fear to practical use cases Ideal applications: Reducing non-value-added tasks Improving efficiency Supporting clinical decision-making preparation (not replacing it) 02:39 — Early Use Cases: Operational Efficiency AI can reduce administrative burden such as: Prior authorizations Insurance-related communications Data gathering and documentation Opportunity to eliminate “busy work” and improve staff satisfaction 03:31 — Clinical Workflow Support AI can: Summarize patient charts, labs, and notes Organize large volumes of clinical data Enables pharmacists to: Spend less time preparing Spend more time in patient care and provider interaction 04:08 — Additional Opportunities: Supply Chain & Operations AI can support: Inventory management Purchasing optimization Multi-site coordination Benefits include: Cost savings Improved efficiency Better resource utilization 05:00 — Where to Draw the Line AI should not replace clinical decision-making Limitations include: Lack of experience and judgment Inability to incorporate patient values and preferences Final decisions must remain with clinicians. 05:42 — Preserving the Human Element Patient care involves: Trust Empathy Relationship-building Over-reliance on AI risks eroding patient confidence. 06:11 — Patient Interaction & Transparency Patients want to know: When AI is used How it impacts their care Transparency and communication are critical 06:48 — AI in Direct Patient Care: Ambient Listening AI tools can: Capture conversations during patient visits Reduce documentation burden Important considerations: Patient consent Ability to opt out Privacy concerns 07:31 — Risks of Poor Implementation Poorly designed AI interactions can: Frustrate patients Reduce trust Healthcare AI must avoid: Impersonal experiences Inefficient automation 08:21 — AI as a Tool, Not a Replacement Comparable to tools like: Search engines (e.g., Google) Enhances efficiency without replacing professional roles. 09:12 — Early Success Stories Prior Authorization Optimization AI improves: Data extraction Documentation speed Approval timelines Benefits: Faster patient access to therapy Improved staff satisfaction 10:07 — Clinical Decision Support Enhancements AI-driven rule systems: Identify high-risk patients Reduce unnecessary chart reviews Example outcome: Reduction in time spent reviewing charts without intervention Frees pharmacists for: Medication reconciliation Patient counseling 11:11 — Impact on Workforce Engagement Staff report: Increased satisfaction More time for meaningful work AI seen as an enabler rather than a threat 12:03 — Vendor Landscape & Challenges Rapid growth of AI vendors addressing niche problems Key risks: Data security concerns Vendor quality variability Overlapping or redundant solutions 12:51 — Integration & Workflow Considerations Successful AI tools must: Integrate with EHRs Align with pharmacy workflows Avoid siloed systems Poor integration leads to inefficiency and adoption barriers 14:04 — Vendor Evaluation Considerations Assess: Clinical and operational expertise Product maturity Implementation effort Risk vs benefit Balance between: Ready-made solutions Custom-built tools requiring internal resources 14:56 — Practical Advice for Health System Leaders Develop a system-wide AI strategy Collaborate across departments (not siloed decisions) Engage: IT Legal Ethics teams Avoid duplicative solutions across service lines 15:31 — Building Organizational Readiness Be open to learning and experimentation Ask questions and maintain healthy skepticism Focus on: Improving workflows Enhancing patient outcomes Supporting workforce engagement 16:02 — Infrastructure & Speed of Innovation AI vendors move quickly Organizations must: Be prepared to adapt rapidly Avoid delays that hinder innovation Balance speed with governance and safety 16:27 — Closing Kerry thanks the guests for their insights Encourages continued exploration of AI's evolving role in healthcare Reminder to subscribe and engage with VerifiedRx. Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pooja Ghatalia, MD Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel approach to response-adapted care. Joining Dr. Charles Turck to review findings from the phase II RETAIN trials, which highlight how ctDNA clearance correlates with improved metastasis-free survival and informs risk stratification, is Dr. Pooja Ghatalia. She also examines the strengths and limitations of ctDNA, including its prognostic value for systemic recurrence and its inability to reliably detect localized disease. Dr. Ghatalia is an Associate Professor in the Department of Hematology and Oncology at Fox Chase Cancer Center at Temple University Hospital in Philadelphia, and she presented this research at the 2026 ASCO Genitourinary Cancers Symposium.
Advancements in hypertension management are shifting the landscape of treatment, from new guideline recommendations to technological innovations. This course explores key highlights from the AHA's recent scientific statements, including single-pill combination therapy and the clinical limitations of some blood pressure devices, alongside updates to the 2025 hypertension guidelines. You will gain a clear understanding of how these changes affect patient care, medication strategies, and pharmacist-driven interventions.Recent ACC/AHA Cholesterol Guidelines further emphasize comprehensive cardiovascular risk assessment and evidence-based management of dyslipidemia alongside other major risk factors such as hypertension. These updates complement the hypertension topics discussed in this episode by reinforcing the importance of coordinated, risk-based approaches to reducing cardiovascular disease. This resource provides a concise, guideline-based overview of hypertension management, summarizing the 2025 ACC/AHA recommendations for blood pressure classification, treatment goals, and stepwise pharmacotherapy. It highlights first- and second-line antihypertensive options, emphasizes individualized, risk-based treatment decisions, and outlines practical considerations for therapy initiation, intensification, and monitoring to optimize cardiovascular outcomes.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTTomasz Jurga, PharmD, BCPS, BCACP, BCCP, HF-Cert, CDCES, AACCClinical Pharmacist PractitionerLTC Charles S. Kettles VA Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify recent guideline and practice updates that may influence the diagnosis, treatment, and monitoring of hypertension.2. Discuss current and emerging tools and strategies that support safe, effective, and individualized hypertension management.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Tomasz Jurga has disclosed that a grant from Merck supported Pharmacy Times Continuing Education activities, including speaking honoraria. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-073-H01-PInitial release date: 4/6/2026Expiration date: 4/6/2027Additional CPE details can be found here.
Advancements in hypertension management are shifting the landscape of treatment, from new guideline recommendations to technological innovations. This course explores key highlights from the AHA's recent scientific statements, including single-pill combination therapy and the clinical limitations of some blood pressure devices, alongside updates to the 2025 hypertension guidelines. You will gain a clear understanding of how these changes affect patient care, medication strategies, and pharmacist-driven interventions.Recent ACC/AHA Cholesterol Guidelines further emphasize comprehensive cardiovascular risk assessment and evidence-based management of dyslipidemia alongside other major risk factors such as hypertension. These updates complement the hypertension topics discussed in this episode by reinforcing the importance of coordinated, risk-based approaches to reducing cardiovascular disease.This resource provides a concise, guideline-based overview of hypertension management, summarizing the 2025 ACC/AHA recommendations for blood pressure classification, treatment goals, and stepwise pharmacotherapy. It highlights first- and second-line antihypertensive options, emphasizes individualized, risk-based treatment decisions, and outlines practical considerations for therapy initiation, intensification, and monitoring to optimize cardiovascular outcomes.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTTomasz Jurga, PharmD, BCPS, BCACP, BCCP, HF-Cert, CDCES, AACCClinical Pharmacist PractitionerLTC Charles S. Kettles VA Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify recent guideline and practice updates that may influence the diagnosis, treatment, and monitoring of hypertension.2. Discuss current and emerging tools Follow CEimpact on Social Media:LinkedInInstagram
In this episode of PING, APNIC Chief Scientist Geoff Huston discusses an emerging concern about how the IETF interprets the concept of ‘Best Current Practice‘ (BCP). In his previous episode, Geoff explored emerging questions around DNS provisioning over IPv6, including experimental observations on its performance characteristics. Towards the end of the discussion, we turned to how the Internet Engineering Task Force documents standards and protocols through Best Current Practice (BCP) publications. In the traditional view, BCPs are intended to provide clear, implementation-focused guidance that remains neutral across different operational contexts. This includes networks of all scales — from home environments to enterprise, national, and international infrastructure. These systems rely on a shared understanding of protocol behaviour, and BCPs help define the set of practical, interoperable choices available for deployment today. To be designated as a BCP, an IETF RFC undergoes additional review and scrutiny. This is similar to the ‘Standard' (STD) designation, which elevates an RFC beyond a general publication and gives it greater weight in operational and procurement contexts. While RFCs are not legally binding, they are frequently referenced in national regulations, procurement frameworks, and service specifications. In contrast, Experimental and Informational RFCs explicitly indicate that they are not intended for such use. BCPs, along with Proposed Standards and Standards, carry greater normative weight due to the more rigorous processes required for their approval, making them more suitable as references for real-world deployment and decision-making. An emerging perspective suggests that BCPs may be treated as aspirational as well as definitional — potentially describing behaviours that are not yet widely deployed, or in some cases not deployed at all. This represents a subtle shift from the traditional view of BCPs as documenting established, operational practice. This tension has surfaced in discussions around the DNS/IPv6 draft mentioned in the earlier PING episode. The conversation involves multiple parts of the IETF process, including the DNSOP Working Group, the DNS Directorate (which reviews DNS-related work across Working Groups) and the Internet Engineering Steering Group (IESG), responsible for final document review and status approval before publication as an RFC. These discussions reflect an evolving question: Should BCPs remain a record of established operational consensus, or can they also serve to guide and shape future practice? Advocacy is an important part of the IETF process. But it's important to distinguish between advocating for a new path in systems and specifying what the current best choice is in the specification of systems behaviour.
Listen in as our expert panel tackles real-world questions about GLP-1 agonists, from starting them and setting expectations with patients to strategies for switching agents. You'll also hear them review key considerations to limit muscle loss with GLP-1 agonist use and discuss why some patients hit a plateau or don't respond to GLP-1 agonists.Special guests:Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, BCACP, CDCES, BC-ADMClinical Professor and Director of Pharmacy EducationUniversity of South Carolina College of PharmacyJennifer M. Trujillo, PharmD, BCPS, FCCP, CDCES, BC-ADMProfessor and the Associate Dean for EducationUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesPanelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityFor the purposes of disclosure Dr. Jennifer Clements reports relevant financial relationships with Novo Nordisk (Ozempic, Rybelsus), Eli Lilly (Zepbound, tirzepatide) [speakers bureau].The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in February 2026.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Madhukar H. Trivedi, MD The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what's actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood Disorders at the University of Texas Southwestern Medical Center in Dallas, Texas. References: Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. Mateos-Aparicio P, Rodriguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66.
Landing that first job feels like the finish line, but for most young professionals, it is really just the beginning. In this episode, Xavier Angel, CFP®, ChFC®, CLTC®, sits down with Christopher Bland, PharmD, FCCP, FIDSA, BCPS, Albert W. Jowdy Professor in Pharmacy Care at the University of Georgia College of Pharmacy, to unpack the real-world financial questions that pharmacists and other graduates face early in their careers. From understanding compensation packages to negotiating pay, evaluating retirement benefits, and using side income strategically, this conversation helps listeners look beyond the headline salary number and make more informed financial decisions from day one. The episode also dives into one of the biggest mindset shifts young earners need to make: high income does not equal wealth. Chris and Xavier discuss how lifestyle inflation, student debt, and poor planning can quietly eat away at even a strong paycheck, while time, discipline, and consistent investing can build real financial freedom over time. It's a practical, honest conversation designed to help young professionals turn early career income into long-term opportunity. Episode Highlights: Christopher shares the one financial lesson he wished he had fully embraced coming out of school: the more time money has to compound, the more profound the long-term impact. (04:00) Christopher breaks down salary versus hourly pay for new pharmacists, noting how hourly work creates flexibility to earn overtime, shift differentials, and supplemental income. (09:07) Christopher recounts landing his first job at the lowest pay tier and explains why the beginning of a career is the most powerful moment to negotiate compensation. (14:54) Christopher encourages students to lean on faculty and mentors for career opportunities, sharing how he connects students with prospects through his own network. (20:09) Xavier explains the difference between Traditional and Roth 401k contributions and stresses the importance of adding a beneficiary to retirement accounts from day one. (25:52) Christopher uses his son's first paycheck experience to illustrate why new earners need an automated plan for their money from the start. (31:32) Christopher outlines three practical steps for young pharmacists: leverage time for investing, negotiate confidently, and evaluate every aspect of a job beyond salary. (38:26) Key Quotes: “As you are young in your career, be developing skills. Seek out these opportunities, network, because then things will begin to flow to you, especially in years, like three to five.” - Christopher Bland, PharmD, FCCP, FIDSA, BCPS “No matter what degree of money you're making, if you have a plan, you're automatically giving yourself a raise.” - Christopher Bland, PharmD, FCCP, FIDSA, BCPS “I want healthcare professionals, pharmacists, to really take ownership of this topic. We work too hard. You've gone to school for too long, to not have a plan for financial freedom and wealth long term.” - Christopher Bland, PharmD, FCCP, FIDSA, BCPS Resources Mentioned: Christopher Bland, PharmD, FCCP, FIDSA, BCPS University of Georgia College of Pharmacy Erik Garcia, CFP®, BFA Xavier Angel, CFP®, ChFC, CLTC Plan Wisely Wealth Advisors
In this episode, we welcome Kirollos Hanna, PharmD, BCPS, BCOP, a recognized leader in oncology pharmacy practice and research. Dr. Hanna shares insights into the evolving landscape of antibody-drug conjugates (ADCs) and the unique challenges they present in managing chemotherapy-induced nausea and vomiting (CINV). As ADC use expands, oncology teams are observing new and sometimes underrecognized patterns of nausea and vomiting, particularly with HER2-directed therapies and delayed-phase symptoms that extend beyond the traditional monitoring window. This discussion highlights how these patterns differ from conventional chemotherapy and what that means for clinical practice. Dr. Hanna also reviews emerging pharmacokinetic data and clinical trial evidence supporting the use of NK1 receptor antagonist–based antiemetic strategies. The conversation emphasizes practical, actionable approaches for optimizing supportive care, improving patient quality of life, and ensuring proactive symptom management within the medically integrated oncology team. Learning Objectives: Describe emerging patterns of chemotherapy-induced nausea and vomiting (CINV) associated with antibody–drug conjugates (ADCs), with emphasis on HER2-directed ADCs and delayed-phase nausea beyond day 5 Discuss pharmacokinetic and clinical trial evidence on NK1 receptor antagonist–based antiemetic strategies when optimizing CINV prevention for patients receiving ADC therapy. This episode offers 0.5 CE credit hours to pharmacists and pharmacy technicians. Claim CE credit here. Guest: Kirollos Hanna, PharmD, BCPS, BCOP, Director of Pharmacy, Minnesota Oncology, Assistant Professor of Pharmacy, Mayo Clinic College of Medicine, Associate Editor, Journal of the Advanced Practitioner in Oncology (JADPRO) Disclosures: Speaker: BeOne, BMS, Exelixis, Pfizer Consulting Fees: BeOne, BMS, Exelixis, Pfizer, Astrazeneca
Join us for a special series featuring speakers and thought leaders from Pharmacy Futures, where we explore the ideas shaping the future of pharmacy practice. In this episode, Megan Adelman, PharmD, BCPS, BCGP, family medicine clinical specialist at the Cleveland Clinic Akron General, discusses opportunities and strategies to incorporate AI tools into the precepting workflow. These practical ideas can be implemented by attendees right away and immediately impact administrative efficiencies, allowing more valuable time with students and residents for in-depth discussions and learning. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Landing that first job feels like the finish line, but for most young professionals, it is really just the beginning. In this episode, Xavier Angel, CFP®, ChFC®, CLTC®, sits down with Christopher Bland, PharmD, FCCP, FIDSA, BCPS, Albert W. Jowdy Professor in Pharmacy Care at the University of Georgia College of Pharmacy, to unpack the real-world financial questions that pharmacists and other graduates face early in their careers. From understanding compensation packages to negotiating pay, evaluating retirement benefits, and using side income strategically, this conversation helps listeners look beyond the headline salary number and make more informed financial decisions from day one. The episode also dives into one of the biggest mindset shifts young earners need to make: high income does not equal wealth. Chris and Xavier discuss how lifestyle inflation, student debt, and poor planning can quietly eat away at even a strong paycheck, while time, discipline, and consistent investing can build real financial freedom over time. It's a practical, honest conversation designed to help young professionals turn early career income into long-term opportunity. Episode Highlights: Christopher shares the one financial lesson he wished he had fully embraced coming out of school: the more time money has to compound, the more profound the long-term impact. (04:00) Christopher breaks down salary versus hourly pay for new pharmacists, noting how hourly work creates flexibility to earn overtime, shift differentials, and supplemental income. (09:07) Christopher recounts landing his first job at the lowest pay tier and explains why the beginning of a career is the most powerful moment to negotiate compensation. (14:54) Christopher encourages students to lean on faculty and mentors for career opportunities, sharing how he connects students with prospects through his own network. (20:09) Xavier explains the difference between Traditional and Roth 401k contributions and stresses the importance of adding a beneficiary to retirement accounts from day one. (25:52) Christopher uses his son's first paycheck experience to illustrate why new earners need an automated plan for their money from the start. (31:32) Christopher outlines three practical steps for young pharmacists: leverage time for investing, negotiate confidently, and evaluate every aspect of a job beyond salary. (38:26) Key Quotes: “As you are young in your career, be developing skills. Seek out these opportunities, network, because then things will begin to flow to you, especially in years, like three to five.” - Christopher Bland, PharmD, FCCP, FIDSA, BCPS “No matter what degree of money you're making, if you have a plan, you're automatically giving yourself a raise.” - Christopher Bland, PharmD, FCCP, FIDSA, BCPS “I want healthcare professionals, pharmacists, to really take ownership of this topic. We work too hard. You've gone to school for too long, to not have a plan for financial freedom and wealth long term.” - Christopher Bland, PharmD, FCCP, FIDSA, BCPS Resources Mentioned: Christopher Bland, PharmD, FCCP, FIDSA, BCPS University of Georgia College of Pharmacy Erik Garcia, CFP®, BFA Xavier Angel, CFP®, ChFC, CLTC Plan Wisely Wealth Advisors
"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities CAR T-Cell Therapy Programs Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes ONS Voice oncology drug reference sheet: Lisocabtagene Maraleucel Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma CAR T-Cell Therapy: Updates in Nursing Management Nursing Considerations in Navigating Patients Receiving CAR T-Cell Therapy ONS book: Guide to Cancer Immunotherapy (second edition) ONS Huddle Cards: Chimeric Antigen Receptor T-Cell Therapy Cytokine Release Syndrome Immune Effector Cell–Associated Neurotoxicity Syndrome Immunotherapy Immuno-Oncology Learning Library American Society of Gene and Cell Therapy: Learning Center American Society for Transplantation and Cellular Therapy: Learning Center National Comprehensive Cancer Network home page To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "CAR T-cell therapy combines an adoptive cell transfer with genetic engineering. And what that really means is that we are harvesting a patient's own T cells and then we engineer them with a synthetic receptor that helps them recognize that cancer. And all of this work has evolved through many decades of stepwise advances in how we design and activate the T cells. That led us to several landmark trials and ultimately the first CAR T-cell therapy approved by the U.S. Food and Drug Administration in 2017, which was tisagenlecleucel for pediatric and young adult patients that had acute lymphoblastic leukemia." TS 3:34 "If a patient has higher disease burden or an inflammatory biology, that does tend to correlate with higher toxicity risk. And then that might influence the way we monitor the patients who are getting the CAR T therapy. And then finally, baseline neurologic examinations, because neurotoxicity can occur with these agents. It's very important that we as a whole healthcare team really understand what the patient looks like at baseline to be able to determine if they're having any altered changes or confusion. If I had to summarize it, we want to confirm the target and make sure that we have the right CAR T product for the patient. We want to confirm that the patient, physiologically and mentally, is ready for the CAR T therapy." TS 10:53 "I think the two [toxicities] that every nurse will hear about almost immediately when talking about CAR T therapy are CRS or ICANS, which stands for immune effector cell–associated neurotoxicity syndrome. ... ICANS can either follow or even occur alongside CRS. And this can present as something as simple as just being slightly confused or altered, leading into progressively more severe elements such as word-finding difficulties, tremors, or changes in handwriting. Or even more severe cases that lead to seizures or decreased levels of consciousness. So, in this setting, neurologic assessments and knowing and understanding what your patient's baseline neurologic status is is so important. Those are really the two largest side effects that cross the board when it comes to CAR T therapies." TS 16:02 "In terms of the more practical aspects of administration, this is not a typical medication infusion. CAR T cells are living cells. So the way they are handled and administered is very specific. The majority of CAR T products are given as a single IV infusion. The cells come to us frozen either from a cellular lab or they will come from the pharmacy department. So those cells are typically thawed, and timing is of the essence. You really need to coordinate the timing of [thawing] to when they get infused to your patient. They tend to have a short shelf life once they're not frozen anymore." TS 26:34 "Now that therapy has, in many places, transitioned to be administered in the outpatient setting, education becomes absolutely critical. The patient is coming for their daily visit to clinic and then they're going home. And it's really up to the caregiver, who is usually not a nurse, who has to recognize early signs of toxicity. They need to be educated about what a fever is, what number constitutes a fever, what does confusion look like, what does hypotension look like? ... Do they have access to a thermometer? If you are asking them to look at blood pressure, do they have access to a blood pressure monitor? And sometimes those can be subtle things that might be overlooked. So, the emphasis in outpatient quality education is teaching those caregivers what to watch for, how to act quickly, and who to call immediately. You need to make sure that they have that information readily available if something happens." TS 30:55
Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSarah Grady, PharmD, BCPS, BCPPProfessor of Pharmacy Practice, Clinical PharmacistDrake University/Broadlawns Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members only.To learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-059-H01-PInitial release date: 3/16/2026Expiration date: 3/16/2027Additional CPE details can be found here.
Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSarah Grady, PharmD, BCPS, BCPPProfessor of Pharmacy Practice, Clinical PharmacistDrake University/Broadlawns Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-059-H01-PInitial release date: 3/16/2026Expiration date: 3/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
Join us for an inspiring session where we explore how the pharmacist's role in medication safety is evolving. Alexis Hayes-Porter, PharmD, MS, BCPS, CPh, Jenna Reynolds, PharmD, BCPS, and Michael Dejos PharmD, MBA, BCPS, CHOP, CPPS, LSSBB, DPLA will also share how ASHP's Practice Advacement Initiative 2030 is being integrated into practice, artificial intelligence's use in advancing medication safety, and tips for student pharmacists on how to get involved in medication safety. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Welcome to this special three-part press coverage series from the Pharmacy Podcast Network, recorded on location at the Pennsylvania Pharmacists Association Annual Conference, held February 20th through the 22nd at the Hilton Harrisburg. This series is proudly sponsored by Value Drug Company and the Pennsylvania Pharmacists Care Network — PPCN — as they celebrate their 10th anniversary of advancing pharmacist-led patient care across the Commonwealth. In this episode we hear from: Margie Lydon - Value Drug Company Darren Mensch, PharmD, BCPS, BCACP Hayleigh Monroe - P4 Pharmacy Student Mayank (Dr. Mak) Amin, PharmD, RPh, MBA Todd Laser - Value Drug Company Jonathan Adly - TJM Labs Jennifer (Pekich) Urso
GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern University Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-081-H01-PInitial release date: 3/9/2026Expiration date: 3/9/2027Additional CPE details can be found here.
GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-081-H01-PInitial release date: 3/9/2026Expiration date: 3/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
There is enormous heterogeneity in clinical outcomes and severity of septic shock, with some patients needing only supportive care in the ICU and others progressing to multiorgan system failure and death. How can clinicians identify patients at higher risk of death? In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn Bulloch, PharmD, BCPS, FCCM, is joined by John A. Kellum, MD, FCCM, to discuss high endotoxin activity as a possible endotype for septic shock. Dr. Kellum's article, “Organ Failure, Endotoxin Activity, and Mortality in Septic Shock,” was published in the September 2025 compendium of Critical Care Explorations. Dr. Kellum is a professor and director of the Center for Critical Care Nephrology, as well as vice chair for the Department of Critical Care Medicine, at the University of Pittsburgh in Pittsburgh, Pennsylvania, USA. The study used a novel biomarker called the endotoxin activity assay (EAA) to detect endotoxin in the blood. While the EAA is not good at identifying patients who are at risk for sepsis, Dr. Kellum said that, when combined with organ failure, it identifies patients at high risk for endotoxic septic shock. In the study, these patients had a mortality rate of 60%. Neither the EAA nor the anti-endotoxin therapy is readily available. And, although endotoxic septic shock is rare, occurring in only a quarter of patients with septic shock, Dr. Kellum hopes that, through precision medicine, segmenting this population into treatable subgroups may allow better diagnostics and opportunities to develop or repurpose therapies in the future. This episode is sponsored by Prenosis. Resources referenced in this episode: Organ Failure, Endotoxin Activity, and Mortality in Septic Shock (Molinari L, et al. Crit Care Explor. 2025;7:e1308) Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis (Seymour CW, et al. JAMA. 2019;321:2003-2017) Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study (TIGRIS) (ClinicalTrials.gov. ID NCT03901807. Last update posted January 9, 2026)
Listen in as our expert panel reviews important concepts behind antimicrobial stewardship along with tips to help limit unnecessary antimicrobial use.Special guests:Madeline King, PharmD, MPH, BCIDPCo-Director, Outpatient Antimicrobial StewardshipCooper University Health CareAssistant Professor of MedicineCooper Medical School at Rowan UniversityMichael A. Deaney, PharmD, AAHIVPInfectious Diseases Clinical Pharmacy SpecialistDenver Health & Hospital AuthorityYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science University For the purposes of disclosure, Dr. Madeline King reports a relevant financial relationship with Shionogi (speakers bureau for cefiderocol).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in January 2026.Use code mt1026 at checkout for 10% off a new or upgraded subscription.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Toolbox: Antimicrobial StewardshipAlgorithm: Investigating Possible Drug AllergyCE Course: Implementing Rapid Diagnostic TestingChart: Antibiotic Therapy: When Are Shorter Courses Better?Send a text*****
In this bonus episode of Medication Talk, join us as we revisit our Notable New Meds of 2025 webinar and highlight two medications that didn't make it into the main podcast—both newly approved antibiotics with important implications for clinical practice.Listen in as our editors take a deeper look at:Gepotidacin (Blujepa) for uncomplicated urinary tract infectionsAztreonam/avibactam (Emblaveo) for complicated intraabdominal‑abdominal infectionsYou'll hear practical insights into where these therapies fit in current treatment approaches, what safety and interaction issues to watch for, and why they matter when resistance limits your options—giving you more confidence when either of these new meds show up in your practice.**No CE Credit is available for this bonus episode.**Use code mt1026 at checkout for 10% off a new or upgraded subscription.******TRC Healthcare Editors: Sara Klockars, PharmD, BCPSStephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC None of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in December 2025. The clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Urinary Tract InfectionsChart: Aztreonam-avibactam (Emblaveo)Article: Keep Boosting Antibiotic Stewardship for Complicated UTIsSend a text*****
You can find more information about Derek Webb, PharmD, and Dennis Williams, PharmD, BCPS, AEC, below:Derek Webb on LinkedInDennis Williams on LinkedInDennis Williams Faculty Page - UNC Eshelman School of PharmacyThis content was independently developed by Pharmacy Times. While we acknowledge the support of our sponsor, all editorial decisions and opinions remain solely those of Pharmacy Times. Any reference to brands is for informational purposes only and not an endorsement.
In this episode, Nick Gazda, PharmD, MS, BCPS, CSP, Director of Pharmacy Oncology and Infusion at Cone Health, discusses how standardized infusion services, centralized medication access, and technology integration have improved patient care and operational efficiency. He also shares strategies for navigating financial and regulatory headwinds while pursuing growth and value-based opportunities in 2026.
The American Diabetes Association's 2026 Standards of Care in Diabetes are here! Let's talk about what's changed and how to better care for our older adults living with diabetes. 2026 Standards of Care in Diabetes: https://diabetesjournals.org/care/issue/49/Supplement_1 Tamara Ruggles, PharmD, BCGP, FASCP: www.linkedin.com/in/tamara-ruggles-491882251 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES: https://www.linkedin.com/in/diana-isaacs-pharmd-bcps-bcacp-bc-adm-cdces-45803426/
© 2020-2026 Ivy Podcast Discovery LLC
